Cipher Pharmaceuticals (CPH) Price Target Lowered to C$4.25 at TD Securities

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) had its price objective decreased by TD Securities from C$5.00 to C$4.25 in a research note published on Monday. TD Securities currently has a hold rating on the stock.

Shares of TSE CPH opened at C$3.50 on Monday. Cipher Pharmaceuticals has a 1 year low of C$3.30 and a 1 year high of C$5.75.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last issued its quarterly earnings data on Thursday, May 10th. The company reported C$0.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of C$0.02 by C$0.01. The business had revenue of C$5.78 million during the quarter, compared to analyst estimates of C$6.00 million. Cipher Pharmaceuticals had a net margin of 32.44% and a return on equity of 75.47%.

In other Cipher Pharmaceuticals news, Director Christian Godin acquired 13,000 shares of the company’s stock in a transaction that occurred on Thursday, March 22nd. The stock was acquired at an average price of C$3.63 per share, for a total transaction of C$47,190.00.

Cipher Pharmaceuticals Company Profile

Cipher Pharmaceuticals Inc, together with its subsidiaries, operates as a specialty pharmaceutical company in Canada. It offers EPURIS (CIP-ISOTRETINOIN), a formulation of the active ingredient isotretinoin for use in the treatment of severe acne; LIPOFEN (CIP-FENOFIBRATE), a formulation of the active ingredient fenofibrate used for the treatment of hyperlipidemia, a cholesterol disorder; and CONZIP/ DURELA (CIP-TRAMADOL ER), a formulation of the active ingredient tramadol for the management of moderate to moderately severe pain.

Receive News & Ratings for Cipher Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cipher Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit